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Abstract
Background Oral mucositis is a serious and debilitating side
effect of conditioning regimens for hematopoietic stem cell
transplant (HSCT). Through HSCT, the homeostasis in the
oral cavity is disrupted. The contribution of the oral micro-
flora to mucositis remains to be clarified. The aim of our
study was to investigate the relationship between yeasts,
bacteria associated with periodontitis, and oral ulcerations
in HSCT recipients.
Methods This prospective observational study included 49
adult HSCT recipients. Twice weekly, oral ulcerations were
scored, and oral rinsing samples were obtained. Samples were
evaluated for the total bacterial load; the Gram-negative bac-
teria: Aggregatibacter actinomycetemcomitans, Porphyromo-
nas gingivalis, Prevotella intermedia, Parvimonas micra,
Fusobacterium nucleatum, Tannerella forsythia, and Trepone-
ma denticola; and the yeasts: Candida albicans, Candida
glabrata, Candida kefyr, Candida krusei, Candida parapsi-
losis, and Candida tropicalis using real-time polymerase
chain reaction with specific primers and probes. Explanatory
variables for oral ulcerations were calculated using the multi-
level generalized estimated equations (GEE) technique.
Results None of the samples was positive for A. actino-
mycetemcomitans, while F. nucleatum was found most often
(66 % of samples). C. albicans was the most isolated yeast
(88 % of samples), whereas C. parapsilosis was found in
only 8 % of the samples. Multivariate GEE analyses identi-
fied P. gingivalis, P. micra, T. denticola, F. nucleatum, C.
glabrata, and C. kefyr as significant explanatory variables of
oral ulcerations.
Conclusions Our data indicate that P. gingivalis in particular,
but also P. micra, T. denticola, F. nucleatum, C. glabrata, and
C. kefyrmay play a role in ulcerative oral mucositis in patients
undergoing HSCT.
Keywords Oral ulceration .HSCT . Periodontal pathogens .
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Introduction
Mucositis remains one of the most common, serious, and
painful side effects of cytotoxic cancer therapy [1]. It is
reported that between 76 % and 89 % of all patients
receiving a myeloablative hematopoietic stem cell transplant
(HSCT) experience oral mucositis [2–4]. Mucositis can be so
painful that patients are not able to eat or drink, and it can
result in a poorer treatment outcome [5].
The pathobiology of mucositis consists of five interde-
pendent stages: initiation, the primary damage response
(messaging and signaling), amplification of damage
responses, ulceration, and finally, healing of the ulcers. Oral
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microorganisms are thought to be involved in the ulceration
phase, where they probably are able to intensify the
inflammatory process and aggravate or promote the
formation of ulcers [6].
Most of the bacterial species present in the oral cavity are
harmless commensal bacteria, and under normal healthy
conditions, there is homeostasis in the oral cavity. In patients
with cancer, this delicate balance can be disturbed by the
cancer itself, the anti-cancer treatment, or by the supportive
therapies that all may contribute to a shift in the oral
microflora of the oral cavity from mainly Gram-positive
to Gram-negative bacteria [7]. This disruption of the
balance may be related to direct cytotoxic effect on
the oral flora, granulocytopenia, altered salivary output,
alteration in cytokine release, use of antibiotics, compromised
oral hygiene, and the acquisition of hospital-associated
pathogens [8]. In the cell wall of Gram-negative obligatory or
facultative anaerobic bacteria including Actinomyces
actinomycetemcomitans, Fusobacterium nucleatum, Por-
phyromonas gingivalis, Parvimonas micra, Prevotella
intermedia, Treponema denticola, and Tannerella for-
sythia, components such as the endotoxin lipopolysac-
charide (LPS) are present. LPS activates macrophages to
produce inflammatory mediators like interleukin 1 (IL-1),
interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α),
prostaglandin E2 (PGE2), and matrix metalloproteinases
(MMPs) [9]. These bacteria are associated with periodontitis
and gingivitis, and they may have the ability to aggravate the
inflammatory process in mucositis.
In addition, oral microbes and cytokines may enter the
bloodstream when the integrity of the oral mucosal barrier is
disrupted and may induce fever and infectious complica-
tions including sepsis [10–12]. Periodontal infections are
also associated with fever and sepsis in patients treated with
high-dose chemotherapy [13]. However, until now, it is
unclear whether there is an association between periodontal
pathogens and mucositis [8].
Candida species and particularly Candida albicans are
also part of the commensal oral flora in a large part of the
population. Between 20 % and 75 % of individuals in the
general population is colonized with Candida species [14].
When the oral homeostasis is disrupted, Candida species
may overgrow and cause local oral infection (candidiasis).
Candidiasis can cause systemic infections and contributes
highly to morbidity in infected patients [15]. Risk factors for
oral candidiasis are immunosuppression, hyposalivation,
local tissue damage, higher age, and wearing dentures
[16–18]. HSCT recipients have several of these risk factors
and are therefore at high risk for developing candidiasis and
invasive Candida infection (candidemias). In a systematic
review, oral yeast colonization is reported to occur in 73 %
of patients treated with high-dose chemotherapy, and candi-
diasis develops in 38 % of these patients [16].
In addition to infections caused by C. albicans, infections
may be caused by non-albicans Candida species such as
Candida glabrata, Candida parapsilosis, Candida tropicalis,
Candida krusei, and Candida kefyr as well [19]. Non-albicans
Candida species are increasing and are estimated to
account for 40–70 % of today's systemic Candida infec-
tions in HSCT recipients with hematological malignan-
cies. Risk factors for candidemias due to C. tropicalis
and C. krusei include neutropenia and HSCT [20]. Al-
though seldom found, C. kefyr has been linked to
bloodstream infections in patients with hematological
malignancies [21, 22]. A recently published study found an
association between C. albicans and oral mucositis in patients
receiving high-dose chemotherapy for hematological malig-
nancies [23].
To the best of our knowledge, no studies have been
performed in which HSCT patients with and without
ulcerations were prospectively followed over time, and
bacterial and fungal analysis of standardized samples
was carried out using sensitive real-time polymerase
chain reaction (PCR). The aim of this prospective, ob-
servational study was to investigate the relationship
between bacteria associated with periodontitis, yeasts,
and oral ulcerations in HSCT recipients using real-time
PCR. Data on the relationship between several patient char-
acteristics, herpes viruses, and oral ulcerations in the same
patient group have been published elsewhere [24].
Patients and methods
Patients
Forty-nine adult patients that underwent HSCT were en-
rolled in this study. All patients were treated for hematolog-
ical malignancies at the Leiden University Medical Center
between November 2006 and June 2009. The study was
approved by the Medical Ethical Committee of the Leiden
University Medical Center, and patients gave their written
informed consent.
T-cell-depleted stem cell transplantation was performed
either with a myeloablative conditioning (MAC) or a re-
duced intensity-conditioning regimen (RIC) [25–27]. Dur-
ing granulocytopenia, all patients received oral digestive
tract decontamination with oral neomycin, polymyxin,
ciprofloxacin, and a neomycin–polymyxin paste or rinse.
Antifungal prophylaxis consisted of oral amphotericin B
tablets in combination with lozenges to be sucked on slowly.
Antistreptococcal prophylaxis with intravenous benzylpeni-
cillin was given 7 days following MAC and continued for
14 days. Pre-emptive antibiotics, consisting of vancomycin
and ceftazidime, were administered when patients devel-
oped a fever. During hospitalization, all patients received
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standardized oral care aimed at preventing the accumulation
of plaque and keeping the oral tissues moist.
Oral assessment and sampling
An oral assessment was performed at least twice weekly
starting before or as soon as possible after the adminis-
tration of the conditioning regimen until hospital dis-
charge. Oral mucositis was scored according to the
criteria of the World Health Organization [28] at eight
non-keratinized anatomical sites (labial and buccal mucosa,
floor of mouth, lateral and ventral tongue, and soft palate) by
one trained dentist (J.E.R-D). Ulcerations present at the
keratinized/specialized mucosa (vermillion borders of
the lip, gingiva, dorsum of the tongue, and hard palate)
were noted separately.
Oral rinsing samples were taken at each oral assessment
using 10 ml of 0.9 % sterile saline solution. Patients were
asked to rinse for 30 s. Samples were frozen at −20°C within
3 h and thereafter stored at −80°C until analysis.
Bacterial and yeast load determination
A total number of 233 rinsing samples were collected, for
90 % of patients varying between two to eight samples. All
samples were thawed and concentrated ten times by freeze-
drying 1 ml of sample and dissolving the residuum in 100 μl
of PCR water (Roche Diagnostics, Almere, The Nether-
lands). DNA was isolated from all samples with the
MagNa Pure LC DNA Isolation Kit III for bacteria
and fungi (Roche Diagnostics) using the MagNa Pure
LC 2.0 instrument (Roche Diagnostics). Bacterial and
yeast loads were determined in duplo by real-time PCR
using the LightCycler® 480-II Instrument (Roche
Diagnostics).
Loads of A. actinomycetemcomitans and F. nucleatum
(reaction A); P. gingivalis and T. forsythia (reaction B); P.
micra, P. intermedia, and T. denticola (reaction C); and C.
albicans and PhHV [36] (reaction D) were determined by
multiplex real-time PCR. PhHV served as an internal con-
trol for DNA extraction and PCR inhibition. Loads of C.
glabrata, C. kefyr, C. krusei, C. parapsilosis, C. tropicalis,
and the total bacterial load were determined by monoplex
real-time PCR (Table 1). All PCRs were carried out in 20-μl
reaction volume containing 10 μl of LightCycler® 480
Probes Master (Roche Diagnostics).
The samples for bacterial analysis were subjected to pre-
incubation cycle of 95°C for 5 min, followed by 45 cycles of
quantification at 95°C for 10 s and at 60°C for 20 s. The
samples for Candida analysis were subjected to a pre-
incubation cycle of 95°C for 10 min, followed by 50 cycles
of quantification at 95°C for 10 s, at 60°C for 30 s, and at
72°C for 30 s.
Serial tenfold dilutions of homologous DNA were
used as standard curves. For quantification, the results
of the samples were calculated using the standard curve
of the corresponding bacterium or yeast. For quantification of
the total bacterial load, a standard curve of A. actino-
mycetemcomitans was used. PCR water was used as a
negative control in every run.
Statistics
Loads are shown as CFU per milliliter of rinsing sample. To
adjust for the unreliability of low positive signals in real-time
PCR, the loads of these samples were set at 80 % of the
detection limit of the corresponding bacterium or yeast. To
adjust for skewness of the data, 10log transformed bacterial
and yeast loads were used in the analysis. Mucositis scores
were recalculated into binary scores: mucositis grade 0–1 was
scored as no ulceration present, and mucositis grades 2–4
were scored as ulceration present. It was not possible to look
at different grades of mucositis as a dependent variable since
some mucositis scores did not occur frequently enough. To be
able to look at shifts in the oral cavity, the absolute loads of the
bacterial and Candida species were recalculated into percen-
tages/ratio in relation to the total bacterial load.
Explanatory variables of oral ulcerations were calculated
using the multilevel binary logistic regression procedure
called the generalized estimated equations (GEE) technique,
with first order autoregressive correlation structure and a
robust estimation procedure. Independent variables were
screened as possible explanatory variables for oral ulcer-
ations using univariate GEE analyses. An independent var-
iable with a p value <0.20 was entered in the multivariate
GEE analysis. A p value <0.05 was considered statistically
significant. All statistical analyses were calculated using
SPSS version 18.0.
Results
Patient characteristics and oral assessment outcomes
The characteristics of the 49 patients that participated in this
study are summarized in Table 2. At 232 (out of 233) time
points, WHO scores involving non-keratinized oral sites
were recorded. Most of the patients (70 %) developed
mucositis during their stay in the hospital. One patient
developed mucositis grade 1 at most, 23 patients experi-
enced peak mucositis of grade 2, seven patients developed
ultimately grade 3 mucositis, and three patients suffered
from a maximum of grade 4 mucositis. Furthermore, 25
patients (51 %) developed an ulceration on the keratinized/
specialized mucosa. At 226 (out of 233) time points, ulcer-
ations on the keratinized mucosa were scored.
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Oral bacterial load
The percentages of positive samples and positive patients
and the measured ranges for the respective bacteria are
shown in Table 3. A. actinomycetemcomitans could not be
found in any of the samples. On the other hand, F. nuclea-
tum was the bacterium that was found most often. All
samples were positive for bacteria. The total load of
periodontal bacteria as a proportion of the total bacterial load
was 1.2 % on average. In about 84 % of the samples, the
proportion of periodontal bacteria was lower than 1 %. In six
samples, the proportion of periodontal bacteria was higher
than 10 %, with a maximum of 63 %.
Candida loads
All patients had samples that were positive for a least one
Candida species during treatment. Only 4 % of the samples
were negative for Candida species. Most patients were
positive for a maximum of four different Candida species.
The percentages of positive samples, patients, and the
measured ranges of Candida loads are shown in Table 4. C.
albicans was found most often, whereas C. parapsilosis was
found the least.
In relationship to the total bacterial load, the ratio of the









































































































































































































































































































































Table 2 Patient characteristics
Number of patients 49
Male 27 (55 %)
Female 22 (44 %)
Age (mean±SD) 48.8 (±13.6) years
Diagnosis
Acute myeloid leukemia 19 (39 %)
Multiple myeloma 10 (20 %)
Acute lymphoblastic leukemia 5 (10 %)
Non-Hodgkin lymphoma 5 (10 %)
Myelodysplastic syndrome 3 (6 %)
Chronic myeloid leukemia 2 (4 %)
Hodgkin lymphoma 2 (4 %)
Chronic lymphocytic leukemia 2 (4 %)
Others 1 (2 %)
Donor type
Matched sibling 17 (35 %)
Matched unrelated 25 (57 %)
Others 4 (8 %)
Conditioning regimen
Myeloablative 25 (51 %)
Reduced intensity 24 (49 %)
Length of stay in the hospital (mean±SD) 27 (±8.9) days
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significant correlation between the total bacterial load and
the total Candida load (Pearson's rho00.026, p00.718).
Explanatory variables of oral ulcerations on non-keratinized
mucosa
The bacterial and Candida species were represented as
explanatory variables in three different ways. First, the
presence or absence for each species was determined and
entered in the GEE analyses. The univariate analyses are
depicted in the second and third columns of Table 5. Inde-
pendent variables with a p value <0.20 in the univariate
analyses were entered together in the multivariate analysis.
When P. gingivalis or C. kefyr was present, the chance of
having an ulceration on the non-keratinized mucosa was
significantly higher.
Secondly, the absolute loads of all species were entered in
the GEE analyses (see Table 5). The results of the multivar-
iate analysis showed that also the load of P. gingivalis and
C. kefyr were significant explanatory variables. The higher
the load of P. gingivalis or C. kefyr, the higher the chance of
an ulceration.
Thirdly, the percentages of bacterial and proportion of
Candida species in relation to the total bacterial load were
entered in the GEE analyses (see Table 5). In the multivar-
iate analysis, the percentages of P. gingivalis, P. micra, T.
denticola, F. nucleatum, and proportion of C. glabrata in
relation to the total bacterial load turned out to be significant
explanatory variables of oral ulcerations on the non-
keratinized mucosa. The total bacterial and total Candida
load were no significant explanatory variables of oral ulcer-
ations on the non-keratinized mucosa.
Explanatory variables of oral ulcerations on keratinized
mucosa
The bacterial and Candida species were represented as
explanatory variables in the same way as for the analyses
regarding ulcerations of the non-keratinized mucosa. The
results of the GEE analyses are shown in Table 6. Looking
at the presence of bacterial and Candida species in the
multivariate analysis, P. gingivalis, P. micra, and C. kefyr
were identified as significant explanatory variables of
oral ulcerations. Also, the load of P. gingivalis and C.
kefyr were significant explanatory variables. However,
when the percentages of bacteria and proportions of
Candida species in relation to the total bacterial load
were considered, none of the possible explanatory spe-
cies were significant in the multivariate GEE analysis.
The total bacterial and total Candida load were no
significant explanatory variables of oral ulcerations on
the keratinized mucosa as well.
Discussion
The results of our study suggest that there is a relationship
between several bacteria associated with periodontitis,
yeasts, and oral ulcerations in HSCT patients. The most
Table 3 Descriptives of the





A. actinomycetemcomitans 0 0 0
P. gingivalis 11 % 20 % 4.15–5.85
P. intermedia 8 % 18 % 2.20–3.53
T. forsythia 31 % 48 % 1.82–5.02
P. micra 43 % 63 % 2.23–5.39
F. nucleatum 66 % 86 % 3.23–5.63
T. denticola 15 % 25 % 3.65–5.94
Total bacterial load 100 % 100 % 4.0–8.38
Table 4 Descriptive properties
of the determined Candida
species
Yeasts Percentage positive samples Percentage positive patients Range (10log CFU/ml)
C. albicans 88 % 94 % 1.08–5.57
C. glabrata 54 % 70 % 2.57–4.12
C. tropicalis 58 % 80 % 1.86–4.44
C. kefyr 56 % 94 % 1.18–1.57
C. krusei 26 % 67 % 2.40–5.48
C. parapsilosis 8 % 25 % 3.18–3.15
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striking result was that the Gram-negative anaerobic bacte-
rium P. gingivalis was a constant explanatory variable and
had a positive predictive value for oral ulcerations. In
addition, the anaerobic bacteria P. micra, F. nucleatum,
and T. denticola and the yeasts C. glabrata and C. kefyr
seemed to be related to oral ulcerations as well.
Table 5 Uni- and multivariate GEE analyses of predictors for ulcer-





p value exp(B) p value exp(B)
Presence P. gingivalis 0.078 1.98 0.007* 3.36
Presence P. intermedia 0.378 1.35
Presence T. forsythia 0.022 0.45 0.115 0.48
Presence P. micra 0.124 0.65 0.333 0.75
Presence F. nucleatum 0.118 0.52 0.377 0.612
Presence T. denticola 0.378 0.72
Presence C. albicans 0.331 1.38
Presence C. glabrata 0.969 0.99
Presence C. kefyr 0.048 1.91 0.029* 2.01
Presence C. tropicalis 0.492 1.18
Presence C. krusei 0.422 1.38
Presence C. parapsilosis a
Load P. gingivalis 0.037 1.17 0.004* 1.37
Load P. intermedia 0.086 1.23 0.355 1.22
Load T. forsythia 0.103 0.85 0.073 0.77
Load P. micra 0.068 0.82 0.056 0.78
Load F. nucleatum 0.402 0.90
Load T. denticola 0.559 0.94
Load C. albicans 0.473 0.93
Load C. glabrata 0.883 0.98
Load C. kefyr 0.055 1.78 0.013* 2.056
Load C. tropicalis 0.396 1.13
Load C. krusei 0.336 1.16
Load C. parapsilosis a
Total bacterial load 0.254 0.86
Total Candida load 0.975 1.00
Percentage P. gingivalis 0.002 1.16 0.001* 1.372
Percentage P. intermedia 0.852 0.46
Percentage T. forsythia 0.563 0.94
Percentage P. micra 0.059 0.11 0.001* 0.00
Percentage F. nucleatum 0.099 1.44 0.015* 1.58
Percentage T. denticola 0.000 0.98 0.000* 0.87
Percentage C. albicans 0.143 1.07 0.080 1.07
Percentage C. glabrata 0.081 1.65 0.000* 3.49
Percentage C. kefyr 0.366
Percentage C. tropicalis 0.297 1.24
Percentage C. krusei a
Percentage C. parapsilosis a
*Significant (p<0.05)
a Could not be determined because of insufficient power for the
analysis of small strata
Table 6 Uni- and multivariate GEE analyses of predictors of ulcer-





p value exp(B) p value exp(B)
Presence P. gingivalis 0.007 3.293 0.005* 4.38
Presence P. intermedia 0.238 2.22
Presence T. forsythia 0.741 0.923
Presence P. micra 0.077 0.54 0.043* 0.46
Presence F. nucleatum 0.657 0.854
Presence T. denticola 0.924 0.959
Presence C. albicans 0.539 0.746
Presence C. glabrata 0.722 0.863
Presence C. kefyr 0.082 0.587 0.005* 0.53
Presence C. tropicalis 0.115 0.619 0.235 0.68
Presence C. krusei 0.788 1.08
Presence C. parapsilosis a
Load P. gingivalis 0.011 1.29 0.034* 0.75
Load P. intermedia 0.134 1.48 0.532 0.79
Load T. forsythia 0.915 1.01
Load P. micra 0.195 0.84 0.094 1.29
Load F. nucleatum 0.611 0.95
Load T. denticola 0.924 1.01
Load C. albicans 0.368 0.85
Load C. glabrata 0.883 0.97
Load C. kefyr 0.047 0.57 0.028* 1.83
Load C. krusei 0.728 1.04
Load C. tropicalis 0.240 0.84
Load C. parapsilosis a
Total bacterial load 0.829 1.02
Total Candida load 0.526 0.89
Percentage P. gingivalis 0.514 0.94
Percentage P. intermedia 0.846 2.57
Percentage T. forsythia 0.979 1.00
Percentage P. micra 0.715 0.46
Percentage F. nucleatum 0.092 1.64 0.162 1.76
Percentage T. denticola 0.117 1.06
Percentage C. albicans 0.087 1.08 0.416 1.07
Percentage C. glabrata 0.096 1.66 0.119 1.70
Percentage C. kefyr 0.606 266.11
Percentage C. tropicalis 0.307 2.14
Percentage C. krusei 0.602 0.19
Percentage C. parapsilosis 0.080 1.22 0.646 0.92
*Significant (p<0.05)
a Could not be determined because of insufficient power for the
analysis of small strata
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The explanatory variables for ulcerations were calculated
in three different ways, since microorganisms can be
involved in infection or disease in different ways. Some
microorganisms cause disease in small numbers, where-
as other microorganisms need to be present in high
numbers to provoke an infection. In addition, a shift
in bacterial composition or the overgrowth of yeasts
may be responsible for disease.
The GEE analysis is a multilevel regression method to
determine the effect that independent variables have on
dependent variables. The explanatory (independent) var-
iables cannot be seen as causative factors. They explain,
but do not cause the dependent variable, in this case
oral ulcerations. Causative variables need to be present
in time before the dependent variables. During the time
of our study, a pre-transplant oral evaluation and sampling,
including periodontal probing, was not part of the stan-
dard of care. Therefore, it was not possible to make
such conclusions from this study.
No clear pattern or association between mucositis and
the oral microflora emerges from literature [8]. Howev-
er, it is difficult to compare studies since they differ on
the populations that were studied, the chemotherapeutic
regimens administered, the sampling and sample analy-
sis methods, the microorganisms studied, the collection
times, and the scoring methods for mucositis. Thus, it is
difficult to compare our results to those of other studies.
Moreover, the bacteria that we studied were not described
previously in relation to mucositis. A. actinomycetemcomi-
tans, P. gingivalis, Prevotella spp., and F. nucleatum were
studied in children receiving chemotherapy, but none of these
species was isolated [37]. The absence of A. actinomycetem-
comitans in the present population is remarkable and may be
due to the antibiotics used. However, in periodontitis patients,
A. actinomycetemcomitans is usually not eradicated by these
antibiotics. Approximately 15–30 % of the normal population
is positive for A. actinomycetemcomitans; thus, patients
positive for A. actinomycetemcomitans were expected in
our patient group as well. Although it cannot be excluded that
A. actinomycetemcomitans was still present in subgingival
biofilms, we do not have a good explanation for the absence
of A. actinomycetemcomitans in the rinsing samples
obtained from our patient group.
P. gingivalis was consistently associated with oral
ulcerations in the present study and had a positive predictive
value. P. gingivalis is present in 10–25 % of healthy
subjects and 53–90 % in periodontitis patients [38, 39].
It possesses several virulence factors like fimbriae that
enables the bacterium to attach to and invade into
epithelial cells, the expression of proteases [40], and
LPS and a polysaccharide capsule that are both highly anti-
genic and can induce the production of pro-inflammatory
cytokines [41, 42]. These virulence factors might be
able to prolong or intensify oral ulcerations or impair
wound healing and that could explain the role of P.
gingivalis in mucositis.
In addition, P. gingivalis may play a role in the initiation
phase of mucositis. Chronic exposure to P. gingivalis may
upregulate the expression of Toll-like receptors (TLR) on
epithelial and endothelial cells in the oral mucosa. Increased
expression of TLR may accelerate the initiation of mucositis
when “CRAMPs” (endogenous damage-associated pattern
molecules released by cells damaged by chemoradiation)
bind to TLR resulting in activation of nuclear factor
kappa-B (NF-κB) [43].
The role of herpes viruses in this patient group was
described elsewhere [24]. There was no association between
HSV-1 and P. gingivalis in these patients. So, the mech-
anism in which both microorganisms are involved in
oral mucositis is thought to be different. Reactivation
of herpes simplex virus type-I (HSV-1) in the oral
cavity most probably causes oral ulcerations in HSCT
patients, while P. gingivalis is supposed to be involved
in the onset of mucositis and in maintaining or intensifying
oral ulcerations.
We found high levels of colonization for all Candida
species except for C. parapsilosis. The levels that we found
were higher than those reported previously for C. albicans,
and much higher for C. glabrata, C. tropicalis, C krusei, C.
kefyr, and C. parapsilosis in patients with hematological
malignancies [17, 19]. Most patients were colonized with
as much as four different Candida species. Others found at
most two different yeast species in oral samples [18]. Most
previous studies used traditional culturing methods, while
we used sensitive real-time PCR. The detection level for
Candida species in our samples was very low, also because
we concentrated the samples ten times. The method we used
probably explains the high level of colonization that we
found. Furthermore, it is feasible that patients in this
hospital have a high degree of colonization.
Only few studies link Candida species with oral
mucositis or ulcerations in HSCT recipients [23, 44].
C. glabrata and C. kefyr have not been described as
being associated to oral ulcerations before. A recently
published study found an association between C. albicans and
oral mucositis in patients receiving chemotherapy for hema-
tological malignancies. In contrast to our study, in this study,
patient samples in the absence of mucositis were not studied
[23]. In children with acute lymphoblastic leukemia, an
association between oral mucositis and Candida species
has been found as well [44].
Although C. kefyr is considered to be a rare species, we
found a very high colonization rate in our patient group
(94 % of patients). Interestingly, the load in almost all
samples was around the detection limit. Data on C. kefyr
colonization are scarce; one study describes the high
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colonization rate of C. kefyr in patients with hematological
malignancies [22]. Furthermore, there are case reports de-
scribing bloodstream infections with C. kefyr [21, 22],
though invasive infections with this species are very rare
at the LUMC. Most previous studies used traditional
culturing methods, which are less sensitive than real-
time PCR we have been using, and low loads could
have been missed. It is also feasible that the primers
and probe for C. kefyr reacted with another yeast as
well. However, cross-reactivity tests in our lab did not reveal
cross-reactivity of our primer-probe set with the other Candi-
da species (C. albicans, C. glabrata, C. krusei, C. parapsilo-
sis, C. tropicalis, and Candida dubliniensis). At the time of
analysis in the laboratory, a search with the Basic Local
Alignment Search Tool (BLAST) did not reveal cross
reactivity with other yeasts as well. Thus, it seems
plausible that this patient group had a high level of
colonization with low loads of C. kefyr.
Despite anti-fungal and antibacterial prophylaxis, all
patients were positive for Candida species, and bacterial
loads were quite high. Resistance of Candida to amphoter-
icin B, which was used prophylactically by our patient
population, was probably not the reason why we found high
levels of colonization, since most Candida species are not
resistant to amphotericin B. However, some strains of C.
krusei and C. kefyr have been reported to display resistance
to amphotericin B [20]. A likely explanation may be a low
compliance to the prophylactic scheme, since patients
reported having difficulty sucking on the amphotericin B
lozenges, particularly when having a dry mouth.
We were not surprised to find high numbers of bacteria
despite antibiotic prophylaxis. Bacteria in an oral biofilm are
difficult to eradicate with systemically administered anti-
biotics because the biofilm highly protects them against an
attack. Furthermore, the bacteria in our study were relatively
insensitive to the antibiotic prophylaxis used, and therefore,
the bacterial load of the less sensitive organisms may be-
come higher. Patients that developed a fever during neutro-
penia received an additional treatment with antibiotics that
may have influenced the composition of the oral flora that
we studied. In spite of all these antibiotic treatments,
patients developed (ulcerative) mucositis, and the associa-
tion with a part of the oral microflora was found.
In literature, there are conflicting results from studies that
used antimicrobials to prevent oral mucositis [7]. These
conflicting results may be due to the selection of inappropriate
antimicrobials for the flora that is important to be eliminated
(e.g., anaerobic Gram-negative bacteria), and the way of
administering the antimicrobials (e.g., systemically versus
locally) may affect the results as well.
In conclusion, P. gingivalis, in particular, but also P.
micra, F. nucleatum, T. denticola, and the yeasts C. glabrata
and C. kefyr are explanatory variables and have a positive
predictive value for mucosal ulcerations in HSCT patients.
Future studies on the role of these microorganisms in
mucositis are warranted.
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